Lawmakers pause PANS/PANDAS coverage bill after debate over prevalence and cost estimates

House bill 1641, a measure addressing coverage for Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS), was presented to the House Health and Human Resources Subcommittee Friday and then passed by for the day while staff and sponsors reconciled prevalence and fiscal estimates.

Delegate (first name not specified in the transcript) introduced HB 1641 noting it had previously been referred to the Health Benefits Review Commission (HERC) for study. The sponsor said HERC and the Bureau of Insurance used data from carriers to estimate prevalence closer to 1 in 11,765 to 1 in 12,000, and that a widely circulated figure of 1 in 200 is decades old and “has been discredited.” The sponsor also referenced a $94,500 budget amendment staff had prepared for state-employee coverage, and told the panel staff would work to verify the numbers for the state plans.

Brad Marsh of the Virginia Bureau of Insurance (BOI) told the committee that BOI’s analysis relied on actual carrier data covering a large share of covered lives in the Commonwealth rather than the older 1-in-200 estimate. BOI staff said their analysis used the largest carriers—representing roughly 80%–90% of covered lives—and that the HERC analysis informed the fiscal estimate included in staff materials.

Families and advocacy groups provided in-person and remote testimony. John Weber, who said his daughter has a degenerative neuromuscular condition that would have been detected earlier if newborn screening had included the test, urged swift action for newborn screening (his testimony was delivered in the section of the transcript addressing newborn screening but witnesses with lived experience also spoke during the PANS/PANDAS discussion). Angie Gentile, a co-founder of the Virginia Alliance for PANS PANDAS Action and mother of a child with PANS, described the disorder’s sudden, severe onset and said her family’s insurance had denied recommended, evidence-based treatments until they paid out of pocket. Christina Nonley, an advisory-council member and parent of four children with PANS/PANDAS, told the committee treatment was effective and urged coverage; she cited HERC/BOI prevalence figures near 1 in 11,765 and said HERC recommended including the condition across health plans, including Medicaid.

After hearing from BOI and advocates, the sponsor and committee agreed to pass the bill by for the day so staff could confirm the prevalence and fiscal figures for the state employee plan and for Medicaid. The transcript records committee agreement to defer further action until staff follow-up.

Why it matters Advocates said denials of insurer-covered, clinician-prescribed treatments were leaving children disabled and families to shoulder out-of-pocket costs for care that, they say, is effective when delivered promptly. The central question for lawmakers is whether the prevalence and projected cost to state health plans are consistent with HERC and BOI analysis; the sponsor sought a short delay so staff could reconcile data before the subcommittee takes final action.

What’s next The committee moved to "pass by for the day" on HB 1641; sponsors and BOI staff will verify prevalence and cost estimates and return to the subcommittee with clarified fiscal analysis and any recommended substitute language.